BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Harvard Business School
Johnson and Johnson
US Department of Justice

Generated: March 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 065149

« Back to Dashboard

NDA 065149 describes PENICILLIN G POTASSIUM, which is a drug marketed by Mylan, Purepac Pharm, Apothecon, Consolidated Pharm, Hanford Gc, Istituto Bio Ita Spa, Lilly, Parke Davis, Pfizer, Sandoz, Watson Labs Inc, Ivax Sub Teva Pharms, Teva, Wyeth Ayerst, and Baxter Hlthcare, and is included in twenty NDAs. It is available from two suppliers. Additional details are available on the PENICILLIN G POTASSIUM profile page.

The generic ingredient in PENICILLIN G POTASSIUM is penicillin g potassium. There are eighty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the penicillin g potassium profile page.
Summary for 065149
Applicant:Hanford Gc
Ingredient:penicillin g potassium
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 065149
Suppliers and Packaging for NDA: 065149
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PENICILLIN G POTASSIUM penicillin g potassium INJECTABLE;INJECTION 065149 ANDA WG Critical Care, LLC 44567-310 N 44567-310-10
PENICILLIN G POTASSIUM penicillin g potassium INJECTABLE;INJECTION 065149 ANDA WG Critical Care, LLC 44567-311 N 44567-311-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1,000,000 UNITS/VIAL
Approval Date:Jul 23, 2009TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength5,000,000 UNITS/VIAL
Approval Date:Jul 23, 2009TE:APRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength20,000,000 UNITS/VIAL
Approval Date:Jul 23, 2009TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
Cantor Fitzgerald
Daiichi Sankyo
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.